Teva Pharmaceutical Industries (NYSE:TEVA) PT Raised to $17.

Teva Pharmaceutical Industries (NYSE:TEVA – Free Report) had its target price increased by Barclays from $15.00 to $17.00 in a report published on Monday morning, Benzinga reports. Barclays currently has an overweight rating on the stock. A number of other research analysts have also recently issued reports on TEVA. HSBC began coverage on shares of […]

Related Keywords

Israel , United States , America , Amir Weiss , Piper Sandler , Money Concepts Capital Corp , Securities Exchange Commission , News Ratings For Teva Pharmaceutical Industries Daily , Jefferies Financial Group , Barclays , Teva Pharmaceutical Industries , Blue Trust Inc , Tower Research Capital , Teva Pharmaceutical Industries Company Profile , Analyst Recommendations For Teva Pharmaceutical Industries , Teva Pharmaceutical Industries Stock Down , Institutional Trading Of Teva Pharmaceutical Industries , Free Report , Moderate Buy , Pharmaceutical Industries Stock Down , Pharmaceutical Industries , Get Free Report , Teva Pharmaceutical , Exchange Commission , Concepts Capital Corp , Research Capital , Wealth Management , Blue Trust , Pharmaceutical Industries Limited , North America , Teva Pharmaceutical Industries Daily , Nyse Teva , Teva , Medical , Boost Price Target , Barclays Plc ,